Aethlon Medical (NASDAQ:AEMD) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a report released on Sunday. The firm issued a sell rating on the medical equipment provider’s stock.

Separately, HC Wainwright reduced their price target on Aethlon Medical from $23.00 to $10.00 and set a buy rating on the stock in a research report on Monday, March 4th.

Aethlon Medical Trading Up 1.5 %

NASDAQ AEMD opened at $0.60 on Friday. The business’s 50-day moving average price is $0.87 and its two-hundred day moving average price is $1.48. Aethlon Medical has a 12 month low of $0.37 and a 12 month high of $5.00. The firm has a market capitalization of $1.57 million, a PE ratio of -0.12 and a beta of 1.60.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.